Adhera Therapeutics, Inc.
ATRX · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | 0.01 |
| FCF Yield | -22.58% | -182.50% | -16.74% | -5.90% |
| EV / EBITDA | -4.11 | 8.14 | 14.97 | 19.76 |
| Quality | ||||
| ROIC | 1.66% | 2.43% | 4.36% | 2.65% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.01 | -1.17 | 0.35 | 0.46 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 90.77% | -1.94% | -102.61% | 73.25% |
| Safety | ||||
| Net Debt / EBITDA | -4.06 | 8.00 | 12.54 | 15.16 |
| Interest Coverage | -0.44 | -0.24 | -0.27 | -0.40 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |